U.S. Markets close in 24 mins
  • S&P 500

    4,544.68
    +8.49 (+0.19%)
     
  • Dow 30

    35,566.01
    -43.33 (-0.12%)
     
  • Nasdaq

    15,204.95
    +83.27 (+0.55%)
     
  • Russell 2000

    2,295.15
    +5.39 (+0.24%)
     
  • Gold

    1,784.30
    -0.60 (-0.03%)
     
  • EUR/USD

    1.1627
    -0.0026 (-0.2209%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • Vix

    15.12
    -0.37 (-2.39%)
     
  • GBP/USD

    1.3786
    -0.0039 (-0.2826%)
     
  • USD/JPY

    113.9690
    -0.3600 (-0.3149%)
     
  • BTC-USD

    63,372.97
    -3,113.39 (-4.68%)
     
  • CMC Crypto 200

    1,501.79
    -32.86 (-2.14%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,708.58
    -29,255.55 (-100.00%)
     

Adamas Announces New Employment Inducement Grants

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EMERYVILLE, Calif., September 10, 2021--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005553/en/

Contacts

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
peter.vozzo@westwicke.com